Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Former FDA official Peter Marks criticized the agency's new risk-based COVID-19 vaccine framework, stating it contradicts the administration's transparency and science standards. The CDC's advisory committee recommended Merck's infant RSV vaccine, and Novavax's approval delay raised concerns about politicization of drug approval processes. Lilly's Verve deal revealed regulatory turmoil following Marks' resignation. Meanwhile, Trump's CDC pick supports vaccine safety, Novartis made a large bet on cardiovascular disease targets, and RFK cut US funding from vaccine alliance Gavi. The biopharma industry is hiring less international talent, and pharma companies face challenges with failed immuno-oncology projects. Evotec is hosting a webinar on preserving quality in the pharmaceutical industry.

Support the show